UBS Group
ALNY icon

UBS Group’s Alnylam Pharmaceuticals ALNY Stock Holding History

UBS Group’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$989K Sell
2,988
-6,000
-67% -$2.04M ﹤0.01% 5567
2025
Q4 		$3.57M Buy
8,988
+6,000
+201% +$2.66M ﹤0.01% 4366
2025
Q3 		$1.36M Sell
2,988
-12,500
-81% -$5.09M ﹤0.01% 5303
2025
Q2 		$5.05M Buy
+15,488
New +$4.29M ﹤0.01% 3869
2024
Q2 		– Sell
-10,000
Closed -$1.49M – 9482
2024
Q1 		$1.49M Buy
10,000
+2,200
+28% +$367K ﹤0.01% 4232
2023
Q4 		$1.49M Buy
+7,800
New +$1.33M ﹤0.01% 4119
2023
Q2 		– Sell
-2,000
Closed -$401K – 8851
2023
Q1 		$401K Hold
2,000
– – ﹤0.01% 4864
2022
Q4 		$475K Buy
+2,000
New +$427K ﹤0.01% 4757
2019
Q1 		– Sell
-34,700
Closed -$2.53M – 7695
2018
Q4 		$2.53M Buy
+34,700
New +$2.67M ﹤0.01% 2804
2017
Q4 		– Sell
-71,000
Closed -$8.34M – 7818
2017
Q3 		$8.34M Sell
71,000
-55,000
-44% -$4.69M ﹤0.01% 1756
2017
Q2 		$10.1M Buy
+126,000
New +$8.05M 0.01% 1539
2015
Q4 		– Sell
-50,800
Closed -$4.08M – 8309
2015
Q3 		$4.08M Buy
50,800
+50,000
+6,250% +$5.56M ﹤0.01% 2088
2015
Q2 		$96K Sell
800
-100
-11% -$11.9K ﹤0.01% 5437
2015
Q1 		$94K Buy
900
+400
+80% +$40.5K ﹤0.01% 5457
2014
Q4 		$49K Buy
+500
New +$46.3K ﹤0.01% 6502

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS Group's ALNY Position: Q1 2026 in Review

UBS Group reduced its Alnylam Pharmaceuticals (ALNY) stake by 44% in Q1 2026, selling an estimated $125M and leaving 458,870 shares worth $152M. The position accounts for 0.02% of the portfolio, ranked #763.

UBS Group first reported a position in ALNY in Q4 2014 and has held it in 46 quarters since. The position peaked at $328M in Q4 2025. 786 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • UBS Group held 458,870 shares of Alnylam Pharmaceuticals worth $152M as of Q1 2026.
  • UBS Group sold 366,970 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $125M.
  • Alnylam Pharmaceuticals made up 0.02% of UBS Group's portfolio in Q1 2026, its #763 holding.
  • UBS Group first reported a position in Alnylam Pharmaceuticals in Q4 2014 and has held it in 46 quarters since.
  • UBS Group's Alnylam Pharmaceuticals position peaked at $328M in Q4 2025.
  • 786 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.